RA | AS | PsA | SLE | SjD | iRMD total | OA | N missing | |
Depression | ||||||||
Depression, physician lifetime diagnosis, % (n) | 28 (630) | 24 (136) | 26 (138) | 33 (52) | 37 (35) | 26 (865) | 21 (5095) | 148 |
Percentage of those with depression treatment by physician or psychologist in the last 12 months (n) | 54 (338) | 50 (68) | 47 (65) | 65 (34) | 49 (17) | 53 (459) | 48 (2449) | 8 |
MINI screen positive, % (n) | 40 (921) | 37 (209) | 41 (212) | 41 (64) | 49 (47) | 39 1288) | 34 (8051) | 256 |
MDD MINI positive* % (n) | 9.5 (215) | 8.5 (48) | 7.1 (40) | 9.7 (15) | 17 (16) | 7.8 (287) | 6.5 (1567) | 24 933* |
PHQ-9 sum score, mean±SD | 5.4±4.7 | 4.9±3.7 | 5.4±4.6 | 6.8±5.2 | 5.4±4.3 | 5.2±4.6 | 4.4±4.0 | 2808 |
PHQ-9 ≥10, % (n) | 13 (304) | 12 (69) | 13 (67) | 24 (38) | 12 (11) | 13 (415) | 9.0 (2173) | 2808 |
Anxiety | ||||||||
Anxiety disorder, physician lifetime diagnosis, % (n) | 16 (369) | 14 (77) | 15 (76) | 17 (26) | 18 (17) | 15 (493) | 11 (2613) | 86 |
GAD-7 sum score, mean±SD | 4.3±4.1 | 3.8±3.8 | 4.3±3.9 | 5.3±4.3 | 4.4±4.0 | 4.1±4.0 | 3.5±3.5 | 2903 |
GAD-7 ≥10, % (n) | 9.2 (210) | 7.9 (45) | 9.4 (49) | 15 (23) | 11 (10) | 8.6 (281) | 5.8 (1389) | 2903 |
Based on NAKO data freeze 100 000; application NAKO-603.
*Only done for Level 2 examination participants with a positive MINI screen.
AS, ankylosing spondylitis; GAD-7, General Anxiety Disorder-7; iRMDs, inflammatory rheumatic diseases; MDD, major depressive disorder; MINI, Mini-International Neuropsychiatric Interview; NAKO, German National Cohort; OA, osteoarthritis; PHQ-9, Depression Scale of the Patient Health Questionnaire; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SjD, Sjögren’s disease; SLE, systemic lupus erythematosus.